4-(1-氮杂环庚烷)-4-氧代丁酸 | 154740-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 4-(1-氮杂环庚烷)-4-氧代丁酸
• 英文名称: butane-4'-carboxy-(1'-hexamethyleneimine)-carboxamide
• 英文别名: succinic acid monoazepane amide；4-(Azepan-1-yl)-4-oxobutanoic acid
• CAS: 154740-93-9
• 化学式: C₁₀H₁₇NO₃
• mdl: MFCD00594274
• 分子量: 199.25
• InChiKey: NQZZZROTIKCZGY-UHFFFAOYSA-N

物化性质

• 沸点：
  400.8±28.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(1-氮杂环庚烷)-4-氧代丁酸 在 lithium hydroxide 、 三甲基乙酰氯 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (S)-1-(4-Azepan-1-yl-4-oxo-butyryl)-pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  Dicarboxylic Acid Azacycle l-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structure−Activity Relationship of the Enzyme−Inhibitor Interactions

  摘要：

  A series of dicarboxylic acid azacycle L-prolyl-pyrrolidine amides was synthesized, and their inhibitory activity against prolyl oligopeptidase (POP) from porcine brain was tested. Three different azacycles were tested at the position beyond P3 and six different dicarboxylic acids at the P3 position. L-Prolyl-pyrrolidine and L-prolyl-2(S)-cyanopyrrolidine were used at the P2-P1 positions. The IC50 values ranged from 0.39 to 19000 nM. The most potent inhibitor was the 3,3-dimethylglutaric acid azepane L-prolyl-2(S)-cyanopyrrolidine amide. Molecular docking (GOLD) was used to analyze binding interactions between different POP inhibitors of this type and the POP enzyme. The data set consisted of the novel inhibitors, inhibitors published previously by our group, and well-known reference compounds. The alignments were further analyzed using comparative molecular similarity indices analysis. The binding of the inhibitors was consistent at the P1-P3 positions. Beyond the P3 position, two different binding modes were found, one that favors lipophilic structures and one that favors nonhydrophobic structures.

  DOI：

  10.1021/jm0500020
• 作为产物：
  描述：

  环己亚胺 在 lithium hydroxide 、 三甲基乙酰氯 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-(1-氮杂环庚烷)-4-氧代丁酸
  参考文献：
  名称：

  Dicarboxylic Acid Azacycle l-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structure−Activity Relationship of the Enzyme−Inhibitor Interactions

  摘要：

  A series of dicarboxylic acid azacycle L-prolyl-pyrrolidine amides was synthesized, and their inhibitory activity against prolyl oligopeptidase (POP) from porcine brain was tested. Three different azacycles were tested at the position beyond P3 and six different dicarboxylic acids at the P3 position. L-Prolyl-pyrrolidine and L-prolyl-2(S)-cyanopyrrolidine were used at the P2-P1 positions. The IC50 values ranged from 0.39 to 19000 nM. The most potent inhibitor was the 3,3-dimethylglutaric acid azepane L-prolyl-2(S)-cyanopyrrolidine amide. Molecular docking (GOLD) was used to analyze binding interactions between different POP inhibitors of this type and the POP enzyme. The data set consisted of the novel inhibitors, inhibitors published previously by our group, and well-known reference compounds. The alignments were further analyzed using comparative molecular similarity indices analysis. The binding of the inhibitors was consistent at the P1-P3 positions. Beyond the P3 position, two different binding modes were found, one that favors lipophilic structures and one that favors nonhydrophobic structures.

  DOI：

  10.1021/jm0500020

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：UNIV MICHIGAN STATE

  公开号：WO2022165198A1

  公开（公告）日：2022-08-04

  A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut portion of the liner is adapted to be removed from the liner when the label is removed from the label-liner combination. Dimensions, and orientation, and a location of the die cut portion in the liner are adapted to allow the label to be removed from the label-liner combination and applied to a surface by digits of a hand without touching an adhesive coating on the backside of the label and adapted to maintain proper printer waste liner spool operations when the liner is wound after application of the label.

  标签-衬底组合中的衬底上提供了一个带有模切部分的衬里。该模切部分与标签的至少一个边缘对齐，衬里的正面附着在标签的背面上。衬里的模切部分适用于在从标签-衬底组合中取下标签时从衬里上取下。衬里中模切部分的尺寸、方向和位置适用于允许使用手指将标签从标签-衬底组合中取下并应用于表面，而不接触标签背面的粘合涂层，并适用于在标签应用后将衬里卷绕时保持适当的打印机废料衬底操作。
• Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease
  作者：Tommi P. Kilpeläinen、Henri T. Pätsi、Reinis Svarcbahs、Ulrika H. Julku、Tony S. Eteläinen、Hengjing Cui、Samuli Auno、Nina Sipari、Susanna Norrbacka、Teppo O. Leino、Maria Jäntti、Timo T. Myöhänen、Erik A. A. Wallén

  DOI：10.1021/acs.jmedchem.3c00235

  日期：2023.6.8

  reducing α-synuclein (αSyn) dimerization and enhancing protein phosphatase 2A activity in a concentration–response manner, as well as reducing reactive oxygen species production. From the best performing oxazoles, HUP-55 was selected for in vivo studies. Its brain penetration was evaluated, and it was tested in αSyn virus vector-based and αSyn transgenic mouse models of Parkinson’s disease, where it

  脯氨酰寡肽酶（PREP）是人体内广泛分布的丝氨酸蛋白酶，可裂解含脯氨酸的肽；然而，最近的研究表明，它对神经退行性病变致病过程的影响源自直接的蛋白质-蛋白质相互作用（PPI），而不是来自其对某些神经肽水平的调节。我们发现了新型非肽类恶唑类 PREP 抑制剂，它偏离了 PREP 抑制剂已知的构效关系。这些新化合物是 PREP 的 PPI 的有效调节剂，以浓度响应方式减少 α-突触核蛋白 (αSyn) 二聚化并增强蛋白磷酸酶 2A 活性，并减少活性氧的产生。从性能最好的恶唑中，选择HUP-55进行体内研究学习。我们评估了它的大脑渗透性，并在基于 αSyn 病毒载体和帕金森病 αSyn 转基因小鼠模型中进行了测试，它恢复了运动障碍并降低了纹状体和黑质中寡聚 αSyn 的水平。
• [EN] PREP BINDING LIGANDS<br/>[FR] LIGANDS DE LIAISON DE PREP
  申请人：UNIV HELSINKI

  公开号：WO2023209191A1

  公开（公告）日：2023-11-02

  The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a disease involving a reduction in PPA2 activity or PP2A dysfunction.

  本发明涉及一类新型的脯氨酰寡肽酶结合配体、包含该配体的药物组合物、所述配体作为药物的用途，特别是但不限于促进自噬和/或治疗涉及 PPA2 活性降低或 PP2A 功能障碍的疾病。
• Polycyclic aromatic compounds as anticancer agents: structure–activity relationships of chrysene and pyrene derivatives
  作者：Bimal K Banik、Frederick F Becker

  DOI：10.1016/s0968-0896(00)00297-2

  日期：2001.3

  A large number of diamides and diamines were synthesized using 6-amino chrysene and 1-amino pyrene as starting materials. A structure-activity study with cis-platinum as internal control against animal and human tumor lines was carried out in vitro. This study indicated that the in vitro cytotoxicity toward these lines depends on the functionality present in the molecules. The diamino compounds were found to be more potent than the diamides, and these were equally active irrespective of the end heterocyclic group, whereas the activity of the diamides was strongly dependent on the terminal unit. In general, the diamides containing chrysene as the chromophore were more active than those with a pyrene ring. The size of the end heterocyclic ring, along with the nature of the spacer connecting the polycyclic ring to the heterocyclic ring, seemed to affect the biological activity in certain cell lines. Hemolysis experiments on a lead compound established that it had activities similar to those described for membrane-stabilizing agents. This agent also demonstrated the capacity to produce differentiation in leukemia cell lines. (C) 2001 Elsevier Science Ltd. All rights reserved.
• PRODRUGS OF ANTIINFLAMMATORY 3-ACYL-2-OXINDOLE-1-CARBOXAMIDES
  申请人：Pfizer Hospital Products Group, Inc.

  公开号：EP0681580A1

  公开（公告）日：1995-11-15